L3VLUP
ProSign in

RYTM · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RYTMJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RYTM
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterRYTMJNJ
Q3 20201 holders, $95m30 holders, $26.2bn
Q4 20201 holders, $134m32 holders, $26.6bn
Q1 20211 holders, $87m31 holders, $25.3bn
Q2 20211 holders, $77m37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 20211 holders, $593k33 holders, $25.2bn
Q1 20221 holders, $474k35 holders, $28.2bn
Q2 20221 holders, $628k33 holders, $26.9bn
Q3 20222 holders, $43m36 holders, $25.4bn
Q4 20221 holders, $36m35 holders, $27.6bn
Q1 2023none listed holders, n.a.42 holders, $24.5bn
Q2 2023none listed holders, n.a.38 holders, $25.0bn
Q3 20233 holders, $33m37 holders, $18.9bn
Q4 20234 holders, $61m31 holders, $19.0bn
Q1 20243 holders, $40m32 holders, $19.7bn
Q2 20244 holders, $32m35 holders, $20.4bn
Q3 20246 holders, $80m28 holders, $22.3bn
Q4 20244 holders, $131m37 holders, $20.4bn
Q1 20254 holders, $147m32 holders, $20.5bn
Q2 20255 holders, $160m31 holders, $18.4bn
Q3 20259 holders, $496m32 holders, $23.7bn
Q4 202510 holders, $537m29 holders, $27.8bn
Q1 20267 holders, $450m34 holders, $35.6bn
Q2 20269 holders, $859m33 holders, $39.1bn
RYTM

Rhythm Pharmaceuticals Inc

Holders
3
Reported value
$40m
Buyers
2
Sellers
0

Breadth +2 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
32
Reported value
$19.7bn
Buyers
16
Sellers
13

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RYTM (1)

Artisan Partners LP

Only JNJ (30)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Caxton Associates LLP, D. E. Shaw & Co., Dodge & Cox, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Renaissance Technologies LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →